https://www.selleckchem.com/products/LBH-589.html
neralocorticoid receptor contributing to right ventricular perivascular fibrosis and smooth muscle cell-mineralocorticoid receptor participating in pulmonary vascular inflammation. As mineralocorticoid receptor antagonists are being investigated to treat pulmonary arterial hypertension, these findings support novel mechanisms and potential mineralocorticoid receptor targets that mediate therapeutic benefits in patients.Pulmonary hypertension is a group of diseases, including pulmonary arterial hypertension associated with congenital hea
Like
Comment
Share
